Abstract: A video image of a processing area of a machine tool is displayed as a moving image on a display screen of a numerical controller, an icon enabling an operator to intuitively recognize a direction in which a movable axis moves is displayed to overlap the moving image, an icon on the display screen corresponding to an operation of a touch panel by the operator is specified, and movement of a movable axis allocated to the specified icon is controlled.

Abstract: The present invention provides a method for predicting the therapeutic effect of chemotherapy using an antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the following steps (1) to (3). As the means for solving the problem, the following invention is provided: a method comprising (1) detecting the expression of TK1 protein by an immunohistochemical method in tumor cells contained in a biological sample obtained from the patient; (2) based on the detection results obtained in step (1), classifying the tumor cells into positive cells and negative cells, and calculating the percentage of positive cells in the tumor cells; and (3) based on the calculation results obtained in step (2), predicting that when the percentage is 30% or more, the patient is likely to sufficiently respond to chemotherapy using the antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5.

Abstract: The present invention intends to provide a printing apparatus that can lessen a reduction in ejection performance caused by thickening, solidification, or the like of print liquid in an ejection port of a printing unit even in the case of stopping a print operation by the printing unit to perform a post-process on a print medium. The printing apparatus includes a post-processing part configured to, in a state of stopping the print operation by the printing unit, perform the post-process on a printed print medium as well as including an open/close unit configured to selectively perform a closing operation or an opening operation of the ejection port provided in the printing unit. Further, when the print medium is stopped in the post-processing part, the open/close unit is controlled so as to bring the ejection port into a close state.

Abstract: A therapeutic agent for inflammatory bowel disease contains, as an active ingredient, a uracil derivative or a pharmaceutically acceptable salt thereof, represented by formula (1) where the R1 and R2 groups are defined in the specification.

Abstract: A holographic reproduction image processing apparatus includes: a detecting section detecting the luminance of a plurality of pixels in an area of a holographic reproduction image extending in a direction substantially orthogonal to a direction in which the image has luminance variation; and an image processing section correcting the luminance variation according to luminance information supplied from the detecting section.

Abstract: To provide an excellent agent for prevention or treatment of an inflammatory disease. The agent for prevention or treatment of an inflammatory disease contains a thymidine phosphorylase inhibitor as an active ingredient, wherein when the thymidine phosphorylase inhibitor is 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a salt thereof, the inflammatory disease is an inflammatory disease other than inflammatory bowel disease.

Abstract: To provide a therapeutic agent for inflammatory bowel disease. The therapeutic agent for inflammatory bowel disease contains, as an active ingredient, a uracil derivative or a pharmaceutically acceptable salt thereof, represented by formula (1).

Abstract: To establish an immunoassay method for human OPRT. The method for assaying human orotate phosphoribosyltransferase protein includes employing, in combination, an anti-human orotate phosphoribosyltransferase antibody which recognizes an epitope present in a region of 86th to 108th amino acid residues from the N-terminus of human orotate phosphoribosyltransferase, and an anti-human orotate phosphoribosyltransferase antibody which recognizes an epitope present in a region of 454th to 474th amino acid residues from the N-terminus of human orotate phosphoribosyltransferase.